Размер шрифта
Цветовая схема
Изображения
Форма
Межсимвольный интервал
Межстрочный интервал
стандартные настройки
обычная версия сайта
закрыть
  • Вход
  • Регистрация
  • Помощь
Выбрать БД
Простой поискРасширенный поискИстория поисков
Главная / Результаты поиска

Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: past, present and future

Moik F., d m. n. A. D., Pabinger I.
Thrombosis Research
Vol.191, P. S3-S11
Опубликовано: 2020
Тип ресурса: Статья

DOI:10.1016/S0049-3848(20)30389-3

Аннотация:
Venous thromboembolism (VTE) is a preventable disease, thus, in a number of clinical situations primary thromboprophylaxis has been proposed. Although we now know that cancer is one of the most important risk factors for VTE, primary prophylactic anticoagulation is only widely established for high-risk hospitalized patients and peri- and postoperatively after major cancer surgery. Long-term primary thromboprophylaxis in ambulatory cancer patients has been demonstrated to be effective. However, drawbacks are the additional burden of drug use, the lack of a reduced mortality benefit and costs. Only with reliable risk prediction the recommendation of primary thromboprophylaxis will convince oncologists and patients of its usefulness. This review deals with clinical and laboratory parameters and their combination in risk assessment models to define patients at high and low risk of VTE, in whom targeted thromboprophylaxis could best be applied. At present 90[%] of patients in the so-called in
Ключевые слова:
Cancer; Cancer-associated thrombosis; Prophylactic anticoagulation; Risk factor; Risk score; Venous thromboembolism
asparaginase; bevacizumab; cisplatin; gemcitabine; tamoxifen; thalidomide; artery thrombosis; Article; bladder cancer; brain cancer; cancer associated thrombosis; cancer patient; clinical feature; clinical practice; colorectal cancer; disease risk assessment; high risk patient; human; intermediate risk patient; Khorana score; kidney cancer; laboratory test; low risk patient; lung cancer; lymphoma; malignant neoplasm; nonhodgkin lymphoma; ovary cancer; pancreas cancer; patient identification; prediction; priority journal; risk prediction; scoring system; stomach cancer; thrombosis prevention; vein thrombosis; venous thromboembolism
Язык текста: Английский
ISSN: 0049-3848
Moik F.
m. n. A. D. m n Ay Dzhikhan 1980-
Pabinger I.
Моик Ф.
м. н. А. Д. м н Ай Джихан 1980-
Пабингер И.
Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: past, present and future
Текст визуальный непосредственный
Thrombosis Research
Elsevier Science Publisher B.V.
Vol.191 P. S3-S11
2020
Статья
Cancer Cancer-associated thrombosis Prophylactic anticoagulation Risk factor Risk score Venous thromboembolism
asparaginase bevacizumab cisplatin gemcitabine tamoxifen thalidomide artery thrombosis Article bladder cancer brain cancer cancer associated thrombosis cancer patient clinical feature clinical practice colorectal cancer disease risk assessment high risk patient human intermediate risk patient Khorana score kidney cancer laboratory test low risk patient lung cancer lymphoma malignant neoplasm nonhodgkin lymphoma ovary cancer pancreas cancer patient identification prediction priority journal risk prediction scoring system stomach cancer thrombosis prevention vein thrombosis venous thromboembolism
Venous thromboembolism (VTE) is a preventable disease, thus, in a number of clinical situations primary thromboprophylaxis has been proposed. Although we now know that cancer is one of the most important risk factors for VTE, primary prophylactic anticoagulation is only widely established for high-risk hospitalized patients and peri- and postoperatively after major cancer surgery. Long-term primary thromboprophylaxis in ambulatory cancer patients has been demonstrated to be effective. However, drawbacks are the additional burden of drug use, the lack of a reduced mortality benefit and costs. Only with reliable risk prediction the recommendation of primary thromboprophylaxis will convince oncologists and patients of its usefulness. This review deals with clinical and laboratory parameters and their combination in risk assessment models to define patients at high and low risk of VTE, in whom targeted thromboprophylaxis could best be applied. At present 90[%] of patients in the so-called in